BRACAnalysis CDx
FDA-approved companion diagnostic for BRCA1/BRCA2 genetic mutations
Software · Cloud SaaSCompany source
Company profile
About Myriad Genetics
Myriad Genetics is a precision medicine company that provides genetic and genomic testing solutions to help patients and healthcare providers make more informed health decisions. The company offers comprehensive testing across five key health areas: hereditary cancer risk assessment, cancer treatment guidance, reproductive health and prenatal care, mental health medication management, and prostate cancer management. Myriad's portfolio includes industry-leading tests such as MyRisk for cancer risk assessment, BRACAnalysis CDx for BRCA mutations, GeneSight for mental health medication guidance, Prequel for non-invasive prenatal testing (NIPT), Prolaris + AI combining genomics with AI-driven digital pathology for prostate cancer, and Precise MRD for minimal residual disease monitoring. The company serves healthcare providers across multiple specialties including oncology, urology, OB/GYN, mental health, and primary care, as well as health systems, biopharma partners, and direct-to-consumer markets. With deep expertise in genetic testing and a commitment to advancing personalized medicine, Myriad Genetics helps unlock the power of genetic information to detect disease early, guide treatment decisions, and prevent disease progression. The company maintains extensive EMR integration capabilities with partners like Epic and Flatiron Health, streamlining test ordering and results delivery within clinical workflows.
Company description Myriad Genetics official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Myriad Genetics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- ADHD
- Anxiety
- Breast cancer
- Chromosome conditions
- Colorectal cancer
- Depression
- Endometrial cancer
- Genetic diseases
- Hereditary cancer
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
Who it serves
- Biopharma companies
- Health systems
- Healthcare providers
- Mental health providers
- OB/GYN practices
- Oncology practices
- Patients/consumers
- Primary care physicians
- Urology practices
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: Epic, Epic Aura, Epic Care Everywhere, Epic Genomics, Flatiron Health OncoEMR, MyChart.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Launch of Prolaris + AI as the first prostate cancer test combining genomics and AI-driven digital pathology for active surveillance management; Partnership with Flatiron Health for OncoEMR integration; Expansion of Epic Aura integration capabilities
Partnerships
Recorded partners
- Epic
- Flatiron Health
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
FirstGene
Genetic testing solution for cancer risk assessment
Software · Cloud SaaSCompany source
Foresight
Comprehensive genetic carrier screening for family planning
Software · Cloud SaaSCompany source
GeneSight
Pharmacogenomic test for mental health medication management
Software · Cloud SaaSCompany source
MyChoice CDx
Companion diagnostic for homologous recombination deficiency testing
Software · Cloud SaaSCompany source
MyRisk
Comprehensive hereditary cancer risk assessment and treatment guidance test
Software · Cloud SaaSCompany source
Precise MRD
Minimal residual disease monitoring for cancer recurrence detection
Software · Cloud SaaSCompany source
Precise Tumor
Comprehensive tumor genomic profiling for personalized cancer treatment
Software · Cloud SaaSCompany source
Prequel
Non-invasive prenatal testing (NIPT) for fetal genetic conditions
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Results of breast cancer risk assessment and hereditary cancer genetic testing in community obstetrics and gynaecology practice following a prospective quality Improvement initiative.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · Dec 1, 2026
Integrating Genetic Testing, Combined Polygenic Risk, and Family History Assessment to Improve High-Risk Breast Cancer Identification in a Community Breast Imaging Center.European journal of breast health · Jul 1, 2026
Characterizing Breast Cancer Prevalence Among Female SDHx Pathogenic Variant Carriers in a Laboratory Research Registry.European journal of breast health · Jul 1, 2026
Cancer Genetic Risk Assessment (CGRA) Certification: Outcomes from the First Six Years.European journal of breast health · Jul 1, 2026
Dating and disclosure in young adults with a hereditary cancer predisposition syndrome: A quantitative analysis.Journal of psychosocial oncology · Jun 27, 2026
Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-Breast.Future oncology (London, England) · Jun 21, 2026
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Early cancer detection
Hereditary cancer risk assessment
Personalized treatment guidance
Cancer treatment decisions
Medication response prediction
Mental health pharmacogenomics
Disease prevention
Risk-based screening and prevention
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Myriad Genetics
Recent articles published on Myriad Genetics's official website.
Using Prostate Cancer Gene Testing to Guide Treatment Decisions: Insights as We Head into 2026
Read on Myriad GeneticsAddressing Provider Misconceptions in Ovarian Cancer Genetic Testing
Read on Myriad GeneticsMore Than Just Risk: Genetic Testing Is Shaping Breast Cancer Treatment
Read on Myriad GeneticsHow Genomic Testing is Transforming Treatment Decisions in Intermediate-Risk Prostate Cancer
Read on Myriad Genetics07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.